Interactive Video Gaming Device Could Aid MS Patients
|
By LabMedica International staff writers Posted on 23 Aug 2016 |

Image: Using Kinect motion-capture camera may improve evaluation of gait pathology in multiple sclerosis patients by increasing objectivity in diagnosis and treatment monitoring (Photo courtesy of the Montreal Neurological Institute & Hospital and McGill University).
A commonly used 3D depth-sensing camera could become a low-cost means of monitoring treatment effectiveness for walking difficulties of patients with gait-impairing diseases such as multiple sclerosis (MS).
The Microsoft “Kinect” motion-detection camera can be hooked up to an Xbox gaming console or a Windows computer for interactive video activities such as tennis and dancing. A team of researchers led by McGill University (Montreal, Quebec, Canada) postdoctoral fellow Farnood Gholami, supervised by Prof. Jozsef Kövecses, collaborated with Daria Trojan, physiatrist at the Montreal Neurological Institute and Hospital, to test whether the Kinect could detect the differences in gait of MS patients compared to healthy individuals. The tool could be useful “to assess treatment effects of certain interventions such as rehabilitation or medication, and to document MS disease progression as reflected by gait deterioration. It may also be useful as a measure in clinical trials,” said Trojan. Additional collaboration was with Behnood Gholami at AreteX Systems Inc. (Hoboken, NJ, USA) and Wassim M. Haddad at Georgia Institute of Technology, (Atlanta, GA, USA).
In current clinical practice, the walking movement of MS patients is usually assessed by their doctors using subjective evaluations that may distort results such that different clinicians may give different evaluations for the same patient. Using computer algorithms that quantify patient walking patterns detected by a camera can reduce potential for human error.
Using Kinect, Dr. Gholami captured the movement of 10 MS patients and 10 members of an age-and-sex-matched control group. The MS patients had previously been assessed for gait abnormalities using the traditional clinician method. Using the data, the team then developed computer algorithms that quantified gait characteristics of MS patients and healthy people. They found that gait characteristics measured with the Kinect camera and analyzed with the developed algorithms were reproducible when assessed at one visit and were different between MS patients and the healthy individuals. Moreover, the gait characteristics of MS patients obtained by the algorithm were correlated with clinical measures of gait. In addition, the algorithms could mathematically define the characteristics of gait in MS patients at different severity levels, accurately determining the level of gait abnormality.
Dr. Gholami became interested in using motion-capture technology for clinical purposes as a PhD student, but the equipment he was using at the time was very expensive, difficult to use, and non-portable, making widespread clinical use prohibitive. Kinect is an inexpensive tool that appears to be accurate enough to do the job. “This tool may help the clinician provide a better diagnosis of gait pathology, and may be used to observe if a prescribed medication has been effective on the gait of the patient or not,” he said, “Our developed framework can likely be used for other diseases causing gait abnormalities as well, for instance Parkinson’s disease.” The next step is to conduct a study with a larger group of MS patients, including evaluation in a gait laboratory, using a newer version of the Kinect device to improve accuracy.
The study, by Gholami F et al, was published July 21, 2016, in the IEEE Journal of Biomedical and Health Informatics.
Related Links:
McGill University
The Microsoft “Kinect” motion-detection camera can be hooked up to an Xbox gaming console or a Windows computer for interactive video activities such as tennis and dancing. A team of researchers led by McGill University (Montreal, Quebec, Canada) postdoctoral fellow Farnood Gholami, supervised by Prof. Jozsef Kövecses, collaborated with Daria Trojan, physiatrist at the Montreal Neurological Institute and Hospital, to test whether the Kinect could detect the differences in gait of MS patients compared to healthy individuals. The tool could be useful “to assess treatment effects of certain interventions such as rehabilitation or medication, and to document MS disease progression as reflected by gait deterioration. It may also be useful as a measure in clinical trials,” said Trojan. Additional collaboration was with Behnood Gholami at AreteX Systems Inc. (Hoboken, NJ, USA) and Wassim M. Haddad at Georgia Institute of Technology, (Atlanta, GA, USA).
In current clinical practice, the walking movement of MS patients is usually assessed by their doctors using subjective evaluations that may distort results such that different clinicians may give different evaluations for the same patient. Using computer algorithms that quantify patient walking patterns detected by a camera can reduce potential for human error.
Using Kinect, Dr. Gholami captured the movement of 10 MS patients and 10 members of an age-and-sex-matched control group. The MS patients had previously been assessed for gait abnormalities using the traditional clinician method. Using the data, the team then developed computer algorithms that quantified gait characteristics of MS patients and healthy people. They found that gait characteristics measured with the Kinect camera and analyzed with the developed algorithms were reproducible when assessed at one visit and were different between MS patients and the healthy individuals. Moreover, the gait characteristics of MS patients obtained by the algorithm were correlated with clinical measures of gait. In addition, the algorithms could mathematically define the characteristics of gait in MS patients at different severity levels, accurately determining the level of gait abnormality.
Dr. Gholami became interested in using motion-capture technology for clinical purposes as a PhD student, but the equipment he was using at the time was very expensive, difficult to use, and non-portable, making widespread clinical use prohibitive. Kinect is an inexpensive tool that appears to be accurate enough to do the job. “This tool may help the clinician provide a better diagnosis of gait pathology, and may be used to observe if a prescribed medication has been effective on the gait of the patient or not,” he said, “Our developed framework can likely be used for other diseases causing gait abnormalities as well, for instance Parkinson’s disease.” The next step is to conduct a study with a larger group of MS patients, including evaluation in a gait laboratory, using a newer version of the Kinect device to improve accuracy.
The study, by Gholami F et al, was published July 21, 2016, in the IEEE Journal of Biomedical and Health Informatics.
Related Links:
McGill University
Latest Technology News
- Training Device Improves Accuracy of Pooled Molecular Diagnostics
- New CE-Certified Software Advances Whole-Genome Cancer Testing
- National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Channels
Clinical Chemistry
view channel
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more
Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
Cancer cells require large amounts of nutrients to grow and proliferate, and amino acids support key processes including protein formation, energy production, and DNA synthesis. Colorectal cancer is marked... Read moreMolecular Diagnostics
view channel
Genomic Fingerprints Reveal Early Chemotherapy Resistance in Childhood Cancer
Chemotherapy remains central to treating childhood cancers, yet its toxic effects can injure healthy tissues, and some tumors later relapse or spread. Clinicians have lacked early molecular markers that... Read more
Blood Gene Expression Fluctuates More Than Expected Over Time
Blood-based gene expression is widely used to explore disease biology, but temporal variability can complicate interpretation of single time-point measurements. Seasonal shifts, time of day, and subclinical... Read more
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read more
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read morePathology
view channel
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read moreIndustry
view channel
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more




 Assay.jpg)



